Tumor and Immune Biomarkers–Based Model to Predict Undetectable MRD and Survival in Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clin. Cancer Res 2022 Jun 13;28(12)2598-2609, C Guerrero, N Puig, MT Cedena, I Goicoechea, C Perez, JJ Garcés, C Botta, MJ Calasanz, NC Gutierrez, ML Martin-Ramos, A Oriol, R Rios, MT Hernandez, R Martinez-Martinez, J Bargay, F de Arriba, L Palomera, AP Gonzalez-Rodriguez, A Mosquera-Orgueira, MS Gonzalez-Perez, J Martinez-Lopez, JJ Lahuerta, L Rosiñol, J Blade, MV Mateos, JF San-Miguel, B PaivaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.